Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cardiac Failure
12%
Cardiovascular Events
100%
Cardiovascular Mortality
12%
Cardiovascular Outcomes
12%
Cardiovascular Risk
12%
Chemoprevention Trial
100%
Colorectal Adenoma
100%
Confidence Interval
25%
Congestive Heart Failure
12%
Cyclooxygenase-2
12%
Cyclooxygenase-2 Inhibitors
12%
Double-blind Trial
12%
Early Separation
12%
Event Rate
12%
Failure Hazard
12%
Hazard Ratio
12%
Large Intestine
12%
Myocardial Infarction
12%
Myocardial Ischemia
12%
Overall Mortality
12%
Placebo
12%
Placebo Groups
25%
Pulmonary Edema
12%
Randomized Placebo-controlled Trial
12%
Relative Risk
25%
Selective Inhibition
12%
Serious Adverse Events
12%
Thrombotic
12%
Thrombotic Events
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Cardiovascular Mortality
12%
Cardiovascular Risk
12%
Colorectal Adenoma
100%
Congestive Heart Failure
25%
COX-2 Inhibitor
12%
Cyclooxygenase 2
12%
Infarction
12%
Lung Edema
12%
Placebo
50%
Polyp
12%
Rofecoxib
100%
Neuroscience
Cardiovascular System
100%
COX-2 Inhibitor
12%
Cyclooxygenase 2
12%
Placebo
50%
Pulmonary Edema
12%